Real-World study tracks breast cancer drug performance outside the lab
NCT ID NCT07243002
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is observing 3,000 people with early-stage HR+/HER2- breast cancer who are taking ribociclib or abemaciclib as part of their routine care. Researchers will look at how long patients stay cancer-free, how well they stick to their medication, and their quality of life. The goal is to understand how these drugs work in real-world settings, not just in controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib and abemaciclib (CDK4/6 inhibitors)
What this could lead to
If successful, this could provide real-world evidence on how well these drugs work and are tolerated outside of clinical trials.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, SW3 6JJ, United Kingdom